3. Business overview – what Beyond Air actually does

Beyond Air is positioned as “the nitric oxide company”: a hybrid of medical device and biopharma built around proprietary technologies to generate and deliver nitric oxide (NO) in hospitals, at home, and in oncology and CNS disorders.

• LungFit PH – the core commercial product: a tankless iNO generator for neonatal intensive care (PPHN), FDA-approved and CE-marked, generating unlimited NO from room air using Plasma Pulse/Ionizer technology. No cylinders, no cassettes.
• LungFit PRO – high-concentration iNO (150–400 ppm) for antimicrobial hospital uses such as viral community-acquired pneumonia and bronchiolitis; early-stage and funding-dependent.
• LungFit GO – at-home iNO device for chronic infections (e.g. NTM lung disease, COPD exacerbations), with prior Cystic Fibrosis Foundation support; advancement currently constrained by financing priorities.
• Beyond Cancer (UNO) – ultra-high concentration NO (>10,000 ppm) delivered intratumorally for solid tumors, with Phase 1a data suggesting a promising survival signal and a Phase 1b combo trial initiated.
• NeuroNOS (now 85% owned by XTL) – small-molecule nNOS inhibitors for autism spectrum disorder and glioblastoma, backed by two Nobel Laureates and Prof. Haitham Amal. It moves out of XAIR’s direct control but still represents potential equity + milestone upside for XAIR.

4. Financials, cash burn and balance sheet

The latest detailed snapshot is Q2 FY26 (quarter ending Sep 30, 2025). Key figures:

• Revenue: 1.8 M USD for the quarter (+128% YoY), almost entirely LungFit PH.
• FY26 revenue guidance: 8–10 M USD.
• Net loss: –7.9 M USD for the quarter (–1.25 USD per share).
• Quarterly net cash burn: ~4.7 M USD.
• Cash + marketable securities (Sep 30, 2025): 10.7 M USD.
• Long-term debt: 10.1 M USD.
• New financing: 12 M USD promissory note (15% interest) plus 20 M USD equity line from Streeterville, lifting pro-forma cash/securities to ~22.9 M USD and extending runway into calendar 2027 (company guidance).

This is a high-burn, high-leverage small cap: even with the NeuroNOS deal and the global LungFit opportunity, XAIR will likely remain dependent on external capital until revenues scale meaningfully.

5. Today’s catalyst – NeuroNOS sold to XTL

The market-moving event behind today’s 170% move is the binding agreement with XTL Biopharmaceuticals regarding NeuroNOS.

• XTL acquires 85% of NeuroNOS (autism + GBM program using nNOS inhibitors targeting NO dysregulation in the brain).
• Beyond Air, as seller, will own 19.99% of XTL’s share capital post-transaction, becoming a strategic shareholder in an autism-focused listed biotech.
• Deal terms include 1 M USD cash plus up to 32.5 M USD in development and commercial milestones payable to Beyond Air if certain clinical and sales thresholds are met.
• NeuroNOS already has two FDA Orphan Drug designations (Phelan-McDermid Syndrome and Glioblastoma), which adds regulatory and exclusivity value.
• Scientific leadership is unusually strong for a micro-cap asset: Prof. Haitham Amal plus two Nobel Laureates in Chemistry on board.

For XAIR shareholders the message is: neuro-CNS development risk and funding burden are shifted to XTL, while XAIR keeps upside exposure via equity + milestones and can focus cash on LungFit PH and oncology NO (UNO).

6. Commercial traction – LungFit PH roll-out

LungFit PH is the foundation of XAIR’s “real business” today. It is the first tankless nitric oxide generator and delivery system that produces iNO from ambient air at the point of care.

• Indication: PPHN in term and near-term neonates – a standard iNO indication but with a new device.
• Regulatory status: FDA approval in the US; CE Mark in Europe and approvals in Australia and multiple other markets.
• Geographic footprint: distribution agreements now cover roughly 35+ countries and are being expanded further (Germany, Brazil and other high-value markets).
• Business model: devices are typically placed via leases/service contracts, with recurring revenue driven by usage and disposables (filters, circuits, etc.).

Even though absolute revenue levels are small, growth rates are high and the company sees LungFit PH as a beachhead to replace cylinder-based iNO systems globally and build a recurring revenue base with better margins over time.

7. Pipeline & upcoming catalysts (2026–2027)

Main value drivers over the next 12–24 months are a mix of device/regulatory milestones and clinical readouts.

• Second-generation LungFit PH: PMA supplement submitted to FDA in June 2025; company guidance is for potential approval and launch before end-2026 (subject to FDA review). This is a major de-risking and commercial optimization milestone.
• International LungFit PH approvals: continued roll-out and local regulatory clearances in Europe, Latin America and Asia (Japan, South Korea, etc.) via distribution partners.
• LungFit PRO: advancement of VCAP/bronchiolitis programs is currently constrained by financing; positive data and a clear funding path could unlock new optionality.
• LungFit GO (NTM / COPD infections): trial design discussions ongoing with FDA; CFF-backed NTM trial data already in; further development depends on capital allocation.
• UNO oncology program (Beyond Cancer): completion and full data from Phase 1a, progression of Phase 1b combos (UNO + PD-1 / CTLA-4) in solid tumors, any early signal of durable responses/survival in checkpoint-refractory patients.

8. Stock performance, volatility and liquidity

XAIR is a classic micro-cap high-volatility biotech/med-tech. Different data sources show a 52-week range roughly between 0.67 and 10.4 USD and a beta close to 1, but intraday moves can be extreme: in the past 24 months the stock has seen both deep drawdowns and +100% daily spikes.

• Float/liquidity: float is relatively small and pre-spike average volume modest (≈100–200k shares), which amplifies moves when news hits and volumes spike into the millions.
• Recent trend: after drifting below 1 USD and facing delisting risk, XAIR has staged several “short-squeeze-like” rallies tied to LungFit progress and financing news, culminating in today’s triple-digit move.
• Practical implication: this is not a stock for size insensitivity – slippage and gap risk are material, and intraday traps are common.

9. Sentiment – retail chatter and social mood

XAIR has a modest but very vocal retail community (Reddit sub r/XAIR, posts on r/pennystocks and Stocktwits). Typical themes:

• Bulls: focus on the “disruptive” nature of LungFit (no cylinders, environmental and workflow advantages), CE Mark and global partnerships, and the idea that a small revenue base can scale rapidly from a few million to tens of millions if adoption accelerates.
• Story-traders: many posts highlight the names involved (Nobel Laureates in NeuroNOS, experienced board members) and analyst targets in the 6–14 USD range, using them as justification for multi-bagger expectations.
• Risks underplayed: discussions often minimize the reality of burn, debt and the need for further capital, sometimes treating financing as “just a bridge” without seriously modeling dilution.

Overall social mood is strongly bullish but non-professional; it can be useful as a barometer of crowd euphoria, not as a source of valuation discipline.

10. Peer group and competitive landscape

There is no perfect one-to-one peer because XAIR mixes NO-based devices, infectious disease, oncology and CNS NO-modulation. However, useful context includes:

• Established iNO players that still rely on cylinders/cassettes, where XAIR is trying to displace installed bases with LungFit PH on a cost/efficiency narrative.
• Other innovative delivery platforms in respiratory care, which often trade at higher EV/sales multiples once they reach 50–100 M USD revenue scale.
• Early-stage oncology platforms (Beyond Cancer UNO) and CNS small-molecule plays (now mostly in XTL via NeuroNOS), which share the same high-risk/high-reward profile typical of micro-cap biotech.

From a “small caps of the moment” angle, XAIR fits squarely in the bucket of highly narrative-driven micro-caps where individual news items (regulatory, deals, financings) can reprice the story by multiples in either direction.

4. Business in breve

Beyond Air è “la società dell’ossido nitrico”: LungFit PH (iNO tankless per PPHN) già approvato FDA e CE, LungFit PRO/GO in sviluppo per infezioni respiratorie, programma oncologico UNO (NO a concentrazioni ultra-elevate intratumorale) e – fino a oggi – NeuroNOS per autismo/GBM ora conferito a XTL.

5. Dati finanziari essenziali

• Ricavi Q2 FY26: 1,8 M USD (+128% YoY), quasi tutto da LungFit PH.
• Perdita netta trimestre: –7,9 M USD; burn di cassa ~4,7 M USD.
• Cash + titoli: 10,7 M USD; debito LT: 10,1 M USD.
• Finanziamento: nota da 12 M + equity line fino a 20 M → cassa pro-forma 22,9 M USD, runway in teoria fino al 2027.

6. Deal NeuroNOS in due righe

XTL compra l’85% di NeuroNOS (nNOS inhibitor per ASD e GBM, con 2 designazioni orfane FDA) e Beyond Air diventa azionista di XTL (19,99%) più potenziale beneficiario di fino a 32,5 M USD di milestone. Di fatto XAIR scarica una parte importante del rischio clinico/finanziario CNS mantenendo upside economico.